Cite
HARVARD Citation
Yin, W. et al. (2022). A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of TAK‐041 in healthy participants and patients with stable schizophrenia. British journal of clinical pharmacology. 88 (8), pp. 3872-3882. [Online].